US 11,684,570 B2
Pharmaceutical ophthalmic compositions
Jeffrey T. Liegner, Boise, ID (US); John Scott Karolchyk, Lake Hopatcong, NJ (US); Bernard Covalesky, Randolph, NJ (US); Richard Dilzer, Long Valley, NJ (US); and Kalian Peters, Flemington, NJ (US)
Assigned to NOVEL DRUG SOULTIONS LLC, Randolph, NJ (US); and EYE CARE NORTHWEST, PA, Sparta, NJ (US)
Filed by NOVEL DRUG SOLUTIONS LLC, Randolph, NJ (US); and EYE CARE NORTHWEST, PA, Sparta, NJ (US)
Filed on Aug. 11, 2022, as Appl. No. 17/819,076.
Application 17/819,076 is a division of application No. 17/084,514, filed on Oct. 29, 2020, granted, now 11,439,590.
Application 17/084,514 is a division of application No. 15/178,812, filed on Jun. 10, 2016, abandoned.
Application 15/178,812 is a continuation in part of application No. 14/227,819, filed on Mar. 27, 2014, abandoned.
Claims priority of provisional application 61/958,170, filed on Jul. 22, 2013.
Prior Publication US 2022/0387308 A1, Dec. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/48 (2006.01); A61K 31/196 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/22 (2006.01); A61K 47/38 (2006.01); A61K 9/00 (2006.01); A61K 31/4709 (2006.01); A61K 38/14 (2006.01); A61K 31/496 (2006.01); A61K 38/12 (2006.01)
CPC A61K 9/0048 (2013.01) [A61K 31/196 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 38/12 (2013.01); A61K 38/14 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 47/38 (2013.01)] 4 Claims
 
1. A pharmaceutical composition, comprising:
(a) a therapeutically effective quantity of triamcinolone or a derivative thereof;
(b) a therapeutically effective quantity of moxifloxacin;
(c) a non-ionic poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) block copolymer having a molecular weight of the polyoxypropylene portion of about 4,000 Daltons and about a 70% polyoxyethylene content, with an overall molecular weight of between about 9,840 Daltons and about 14,600 Daltons, wherein the concentration of the non-ionic poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) block copolymer is between about 1 mass % and about 2 mass % of the pharmaceutical composition;
(d) about 1% of polysorbate 80; and
(e) a pharmaceutically acceptable carrier.